=> d l6 tot bib abs hitstr

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:874421 CAPLUS
DN 145:376982
TI Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists
AU Ma, Vu; Bannon, Anthony W.; Baumgartner, Jamie; Hale, Clarence; Hsieh, Faye; Hulme, Christopher; Rorrer, Kirk; Salon, John; van Staden, Carlo; Tempest, Paul
CS Chemistry Research and Discovery, Amgen Inc., Thousand Oaks, CA, 91320, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(19), 5066-5072
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 145:376982
AB Melanin-concentrating hormone (MCH) is a cyclic 19 amino acid orexigenic neuropeptide. The action of MCH on feeding is thought to involve the activation of its resp. G protein-coupled receptor MCH-R1. Consequently, antagonists that block MCH regulated MCH-R1 activity may provide a viable approach to the treatment of diet-induced obesity. This communication reports the discovery of a novel MCH-R1 receptor antagonist, which was identified through high throughput screening. The solid-phase synthesis and structure-activity relationship of related analogs is described.
IT 846020-68-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solid phase synthesis and structure-activity relationships of biarylethers as melanin-concentrating hormone receptor-1 antagonists identified through high throughput screening)
RN 846020-68-6 CAPLUS
CN Benzamide, 4-(3,4-dimethylphenoxy)-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:315070 CAPLUS
DN 145:285
TI Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists
AU Kanuma, Kosuke; Omodera, Katsunori; Nishiguchi, Mariko; Funakoshi, Takeo; Chaki, Shigeyuki; Nagase, Yasuko; Iida, Izumi; Yamaguchi, Jun-ichi; Semple, Graeme; Tran, Thuy-Anh; Sekiguchi, Yoshinori
CS Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd, Saitama, Saitama, 331-9530, Japan
SO Bioorganic & Medicinal Chemistry (2006), 14(10), 3307-3319
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier B.V.
DT Journal
LA English
AB The optimization of the distance between two key pharmacophore features within our first hit compds. led to the identification of a new class of potent non-peptidic antagonists for the MCH-R1, based around 4-amino-2-cyclohexylaminoquinazolines. In particular, ATC0065, N 2-[cis-4-({2-[4-Bromo-2-(trifluoromethoxy)phenyl]ethyl}amino)cyclohexyl]-N4,N4-dimethylquinazoline-2,4-diamine dihydrochloride, bound with high affinity to the MCH-R1 (IC50 value of 16 nM) and showed good metabolic stability in liver microsomes from human and rat.
IT 617245-27-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists)
RN 617245-27-9 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:182684 CAPLUS
DN 142:254663
TI Amine-containing phenyl derivative melanin-concentrating hormone receptor antagonists for therapeutic use

IN Tempest, Paul; Hulme, Christopher; Ma, Vu
PA Amgen, Inc., USA
SO PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019240	A2	20050303	WO 2004-US25970	20040811
	WO 2005019240	A3	20050506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004266228	A2	20050303	AU 2004-266228	20040811
	AU 2004266228	A1	20050303		
	CA 2534428	A1	20050303	CA 2004-2534428	20040811
	US 2005256161	A1	20051117	US 2004-916219	20040811
	EP 1654225	A2	20060510	EP 2004-780754	20040811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2007502283	T	20070208	JP 2006-523322	20040811
	MX 2006PA01638	A	20060428	MX 2006-PA1638	20060210
PRAI	US 2003-494855P	P	20030813		
	WO 2004-US25970	W	20040811		

OS MARPAT 142:254663
GI



I

AB The title compds., or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, are provided. Also provided are methods for treating or

preventing a melanin-concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of the invention. Preparation of compds, e.g. I, is described.

IT 846020-68-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amine-containing Ph derivative melanin-concentrating hormone receptor antagonists for therapeutic use)

RN 846020-68-6 CAPLUS

CN Benzamide, 4-(3,4-dimethylphenoxy)-3-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:767279 CAPLUS

DN 141:405643

TI 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists

AU Receveur, Jean-Marie; Bjurling, Emelie; Ulven, Trond; Little, Paul Brian; Norregaard, Pia K.; Hoegberg, Thomas

CS 7TM Pharma A/S, Horsholm, DK-2970, Den.

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(20), 5075-5080
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 141:405643
AB Synthesis, in vitro biol. evaluation and structure-activity relationships of 4-acylamino-and 4-ureidobenzamides as novel hMCH1R-antagonists are disclosed. The nature of the amine side chains could be varied considerably in contrast to the central benzamide scaffold and aromatic substituents.
IT 617244-41-4 617245-26-8 617245-27-9
617245-56-4 617246-58-9 617246-60-3
791613-58-6
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists)
RN 617244-41-4 CAPLUS
CN Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 617245-26-8 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 617245-27-9 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RN 617245-56-4 CAPLUS
CN Benzamide, 2-methoxy-N-[3-(4-morpholinyl)propyl]-4-[[[(3-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 617246-58-9 CAPLUS
CN Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 617246-60-3 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 791613-58-6 CAPLUS
CN Benzamide, 2-methoxy-4-[[[(2-phenoxyphenyl)amino]carbonyl]amino]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:837034 CAPLUS
DN 139:337786
TI Preparation of novel benzamides for use in MCH receptor related disorders
IN Ulven, Trond; Hoegberg, Thomas; Elling, Christian E.; Norregaard, Pia Karina; Bjurling, Anna Emelie; Receveur, Jean-Marie; Little, Paul Brian
PA 7TM Pharma A/S, Den.
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087044	A2	20031023	WO 2003-DK232	20030408
	WO 2003087044	A3	20041104		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003226927	A1	20031027	AU 2003-226927	20030408
PRAI	DK 2002-518	A	20020409		
	DK 2002-757	A	20020516		
	WO 2003-DK232	W	20030408		

OS MARPAT 139:337786
GI



I



II

AB Title compds. I [wherein A = a linker, e.g. CHR7CONR7, CONR7, OCONR7, SO2NR7, CHR7NR7CO, NR7CONR7, hexahydro-2-oxo-pyrimidine-1,3-diyl, 2-oxoimidazolidine-1,3-diyl, 1,2,4-oxadiazolediyl, 1,3,4-oxadiazolediyl, (un)substituted imidazolediyl or 1,2,4-triazolediyl, CH=CH, OCHR7, NR7CHR7, or SCHR7; B = CH2, OCH2, O, SO2, NR7, S, NR7CH2, SCH2, CONR7, SO2NR7, CO, or CHOR7; Ar1 and Ar2 = independently (hetero)aryl; R1 and R2 = independently H, halo, CF3, OCF3, SCF3, SMe, nitrile, alkyl, alkenyl, or alkynyl; or R1 and R2 may be connected to each other to form annelated rings; R5 and R6 = independently H, halo, alkoxy, OH, (di)alkylamino, hydroxyalkyl, carboxamido, acyl(amido), CHO, nitrile, alkyl, alkenyl, alkynyl, SMe, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)thioalkoxy, SO2NH2, (di)alkylaminosulfonyl, or alkylsulfonyl; more than one R5 and/or R6 may

be present; Q = substituted amino; R7 = independently H, alkyl, or alkenyl; n = 1-3; and physiol. acceptable salts, complexes, solvates, and prodrugs thereof] were prepared as melanin-concentrating hormone (MCH) receptor modulators. For example, coupling of 4-aminobenzoic acid with 4-phenoxyphenyl isocyanate in DCM gave 4-[3-(4-phenoxyphenyl)ureido]benzoic acid (79%). Condensation of the acid with 2-(aminomethyl)-1-ethylpyrrolidine afforded the ureidobenzamide II (34%). In assays of [125I]-MCH binding and phosphatidylinositol turnover using transiently transfected COS-7 cells or stably transfected CHO cells expressing the human MCH-1 receptor, II exhibited activity with IC50 values of 0.25 μM and 1.3 μM, resp. Thus, I and their pharmaceutical compns. are useful in the treatment or prevention of obesity, depression, diabetes, bulimia, and other MCH receptor related disorders (no data).

IT 617246-50-1P 617246-51-2P 617246-52-3P
617246-55-6P 617246-57-8P 617246-58-9P
617246-60-3P 617246-62-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MCH receptor modulator; preparation of benzamides as MCH receptor modulators for treatment of obesity, depression, diabetes, bulimia, and related disorders)

RN 617246-50-1 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 617246-51-2 CAPLUS
CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 617246-52-3 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 617246-55-6 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[[4-(phenylmethyl)-2-morpholinyl]methyl]- (CA INDEX NAME)



RN 617246-57-8 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 617246-58-9 CAPLUS
CN Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 617246-60-3 CAPLUS
CN Benzamide, 4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-N-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 617246-62-5 CAPLUS
CN Benzamide, N-methyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)